Miami’s Newest Innovative Boutique Advertising Agency To Represent Infobae In The United States

August 12, 2014

Miami’s Newest Innovative Boutique Advertising Agency To Represent Infobae In The United States

Argentina’s leader in digital media joins forces with Glo Creative

MIAMI, Aug. 12, 2014 /PRNewswire-HISPANIC PR WIRE/ — Glo Creative, Miami’s newest boutique advertising agency, has opened its doors with a bang. From representing the most prominent yacht brands to helping launch Newsmax TV network, Glo Creative has stepped up to the challenge of providing world-class creative thinking for rising brands.

And in the agency’s most recent endeavor, the creative powerhouse has formalized a strategic alliance with Infobae.com, Argentina’s leader in digital media. And it is no coincidence that Miami, a city with such a strong Latin American influence, was selected as the operations hub for Infobae.com – making this alliance with Glo Creative the perfect fit.

Infobae.com has emerged as an innovator in the media landscape through implementing progressive technology to engage readers with the most important news stories of the day. Recognized as an internet success story in 2013 by comScore, the website boasts more than 17 million visits per month, an average of 15 minutes spent on the website per visit and a great social media presence with 945 thousand Facebook “likes” and 1.1 million Twitter followers. Daniel Hadad, owner of Infobae.com and Sebastian Darcyl, President of Glo Creative, established this partnership offering quality content for Spanish-speaking audiences, and blending the reach of digital media with the best of advertising creativity.

“Glo Creative is excited to add such an innovative company to our client roster,” said Sebastian Darcyl, President of Glo Creative. “They have a great story to tell and we are eager to help establish the Infobae.com brand in the U.S. and Latin American markets through cutting edge advertising and marketing solutions.”

Glo Creative is the brainchild of Argentinean business entrepreneur, Sebastian Darcyl and former New York advertising creative, Michael Glovaski. Sebastian, one of Argentina’s most dynamic entrepreneurs and film industry moguls, brings a keen business sense, while Michael brings over two decades of creative experience. Michael is a well-known creative director behind many successful advertising campaigns including electronic giant Samsung, Subway and Phillips Electronics.

This is only the beginning for Glo Creative, an agency that is progressively expanding its client roster to represent an array of luxury brands utilizing collective creative talent across 360° platforms. For more information or to inquire about Infobae.com advertising rates, please visit www.glocreative.com, email [email protected] or call 305.347.5130.

John Oliver, Emmy Award-Winning Comedian and Host of HBO’s New Hit Show Last Week Tonight With John Oliver, Announces Fall 2014 Tour

August 12, 2014

John Oliver, Emmy Award-Winning Comedian and Host of HBO’s New Hit Show Last Week Tonight With John Oliver, Announces Fall 2014 Tour

– Tickets go on sale on Friday, August 15, 2014 –

LOS ANGELES, Aug. 12, 2014 /PRNewswire-HISPANIC PR WIRE/ — John Oliver, the host of HBO’s Last Week Tonight With John Oliver, announced today a 15-date tour visiting theaters throughout the U.S. Tickets go on sale Friday, August 15 starting at 10:00 a.m. at www.livenation.com and through the Live Nation mobile app. For more information about John Oliver and the tour, please visit, www.iamjohnoliver.com.

Photo – http://photos.prnewswire.com/prnh/20140811/135249

John Oliver is an Emmy and Writer’s Guild Award-winning writer. His HBO show, Last Week Tonight with John Oliver, presents a satirical look at the week in news, politics and current events. On his occasional breaks from television, John returns to his first love of stand-up and plays to sold-out venues across the US.

From 2006 to 2013, John was a correspondent and guest host on the multi-award winning The Daily Show with Jon Stewart. He first came to prominence as a cutting-edge political stand up in the UK, with a string of television appearances and sold-out solo shows at the Edinburgh Festival. Having made the move to America in 2006 to work on The Daily Show, John won the Breakout Award at the Aspen Comedy Festival in 2007 and went on to write and star in his first hour long Comedy Central stand up special John Oliver: Terrifying Times in 2008. Such was its success that John has now hosted four seasons of his own stand up series for Comedy Central, John Oliver’s New York Stand Up Show, featuring a hand-picked selection of his favorite comedians.

With long-time collaborator Andy Zaltzman, John co-writes and co-presents the hugely popular weekly satirical podcast The Bugle. Its success has grown significantly since its inception in 2007 and now pulls in over 500,000 downloads a week. John and Andy previously wrote and starred in three series of The Department (BBC Radio 4) alongside Chris Addison, as well as two series of BBC Radio 4 show Political Animal, based on their satirical live stand-up show.

John also continues to successfully tour the U.S. as a stand up. He has a regular guest role on NBC’s sitcom Community, is the voice of Vanity Smurf in The Smurfs movie and its sequel The Smurfs 2,and has recently appeared in The Simpsons as Marge and Homer’s next-door neighbor, Booth Wilkes-John.

“Oliver is a master storyteller, stringing jokes together so tightly that not a syllable falls out of place.”
The Onion

“The most intelligent political stand-up you’ll see this year.”
The Times

Follow John on Twitter at @iamjohnoliver.

JOHN OLIVER FALL 2014 TOUR DATES: *All dates, cities and venues below subject to change.

Show Date	City	Venue
November 18, 2014	Buffalo, NY *	University of Buffalo
November 19, 2014	Denver, CO	Temple Hoyne Buell Theatre
November 20, 2014	Anaheim, CA*	The Grove
November 21, 2014	Santa Rosa, CA	Wells Fargo Center for the Arts
November 22, 2014	Portland, OR	Keller Auditorium
November 23, 2014	Seattle, WA	Paramount Theatre
December 04, 2014	Atlanta, GA	Cobb Energy Performing Arts Centre
December 05, 2014	Durham, NC	Durham Performing Arts Center
December 06, 2014	Columbus, OH	Palace Theatre
December 07, 2014	Madison, WI	Orpheum Theatre
December 12, 2014	Westbury, NY	Theatre at Westbury
December 13, 2014	Albany, NY	Palace Theatre
December 14, 2014	New Brunswick, NJ	State Theater
December 30, 2014	Boston, MA*	Wilbur Theatre
December 31, 2014	Boston, MA*	Wilbur Theatre
* = Non Live Nation date

About Live Nation Entertainment
Live Nation Entertainment (NYSE: LYV) is the world’s leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation & House of Blues Concerts, LN Media and Artist Nation Management. For additional information, visit: www.livenationentertainment.com.

(Español) Animal Planet revive gigantes en el estreno mundial de la serie REDWOOD KINGS

August 12, 2014

Sorry, this entry is only available in Español.

Herradura Invites Artists to Transform Tequila Oak Barrels into Works of Art

August 11, 2014

Herradura Invites Artists to Transform Tequila Oak Barrels into Works of Art

Herradura Barrel Art Collection to Award over $100K to Artists and $70K to Charity

LOUISVILLE, Ky., Aug. 11, 2014 /PRNewswire-HISPANIC PR WIRE/ — Tequila Herradura, one of Mexico’s most historic and renowned ultra-premium tequilas, announced today the launch of its second annual “Barrel Art Collection.” The program gives artists an opportunity to create original art pieces using Tequila Herradura’s oak barrels as their medium. Artists in Atlanta, Austin, Chicago, Los Angeles, Miami, New York, and San Francisco are invited to participate for a chance to win $10,000 per market. To further demonstrate Herradura’s commitment to art, the brand will donate $70,000 to Creative Capital, an organization that supports innovative and adventurous artists nationwide through funding, counsel and career development services.

Photo – http://photos.prnewswire.com/prnh/20140811/135200

“At Casa Herradura we mature our tequila in oak barrels and consider the finished product a true work of art,” said Mark Grindstaff, Brand Director, Tequila portfolio. “We are thrilled to create a platform where artists can use these same barrels as their medium for creating unique pieces to be showcased for our fans.”

Consumers in each key market will have an opportunity to see these creations in their markets. All participating artists will be given an empty oak barrel to serve as the canvas for their inspiration. First place winners in each city will receive $10,000; second place will receive $3,000; and third place will be honored with $1,000. Each local competition will be judged by art critics, aficionados, collectors and friends of Tequila Herradura who have an interest or love for art. Artists’ works will be judged based on originality, creativity, overall quality and inclusion of elements and values that represent Tequila Herradura.

“It’s amazing that a brand like Herradura supports artists in such a dramatic and positive way,” said Micah and Whitney Stansell, 2013 grand prize winners. “Through the Barrel Art Challenge, our artistic capabilities were brought to life with this unique opportunity that posed no limits. From meeting different artists and making new friends, to the grand finale event we had a great experience and would recommend it to anyone.”

Artists interested in participating need to contact Heather Kleisner at [email protected] and provide a bio, imagery of artwork, or a link to their website. Click here to view the 2013 Herradura Barrel Art artist video: http://youtu.be/mmhY8Bn3lwY.

About Tequila Herradura

Tequila Herradura is an ultra premium 100% agave tequila crafted using traditional production methods. Crafted by Casa Herradura using only the most mature blue agave and artisanal methods, such as slowly cooking the agave in traditional clay ovens and fermenting naturally with wild yeast. Only naturally occurring airborne yeast produced by the agave plantations and fruit trees surrounding the distillery influence the fermentation process. Casa Herradura is one of Mexico’s most historic and renowned tequila producers. Casa Herradura has been hand harvesting, handcrafting and estate bottling fine tequilas from the small town of Amatitán, Jalisco since 1870. For more information, visit www.Herradura.com.

About Creative Capital

Creative Capital supports innovative and adventurous artists across the country through funding, counsel and career development services. Since 1999, they have committed $29 million in financial and advisory support to 419 projects representing 529 artists, and their Professional Development Program has reached more than 6,000 artists in 160+ communities. For more information, visit www.creative-capital.org.

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

August 11, 2014

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone

RARITAN, N.J., Aug. 11 2014 /PRNewswire-HISPANIC PR WIRE/ — Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET^™, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes. INVOKAMET^™ provides the clinical attributes of INVOKANA^® (canagliflozin), the first sodium glucose co-transporter 2 (SGLT2) inhibitor available in the United States, together with metformin, which is commonly prescribed early in the treatment of type 2 diabetes. INVOKAMET^™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7288451-janssen-pharmaceuticals-fda-approved-invokamet-type-2-diabetes

“INVOKAMET^™ combines, in one tablet, two complementary therapeutic approaches proven effective for managing type 2 diabetes,” said Richard Aguilar, M.D.*, Medical Director of Diabetes Nation. “Canagliflozin works with the kidney to promote the loss of glucose in the urine, whereas metformin decreases the production of glucose in the liver and improves the body’s response to insulin.”

INVOKAMET^™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled by treatment that includes either canagliflozin or metformin, or who are already being treated with both canagliflozin and metformin as separate medications. INVOKAMET^™ should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Study results demonstrated that administration of INVOKAMET^™ was equivalent to co-administration of corresponding doses of canagliflozin and metformin as individual tablets.

INVOKAMET^™ will be available in tablets containing canagliflozin 50 milligrams (mg) or 150 mg, and metformin 500 mg or 1000 mg. The recommended dosing is twice daily. The prescribing information for INVOKAMET^™ also contains a boxed warning for lactic acidosis, a rare, but serious complication that can occur due to metformin accumulation.

“As with INVOKANA^®, INVOKAMET^™ provides adults with type 2 diabetes an oral therapy that lowers blood sugar and is also associated with reductions in body weight and systolic blood pressure,” said Jimmy Ren, Ph.D., Therapeutic Area Lead, Metabolics, Medical Affairs, Janssen Pharmaceuticals, Inc. “The available doses of INVOKAMET^™ allow physicians to tailor therapy for individual patient needs and offer an alternative for patients who may be able to reduce the number of tablets they take each day.”

In March 2013, the FDA approved canagliflozin — INVOKANA^®— as a single agent, and it is the number-one branded non-insulin type 2 diabetes medication newly prescribed by U.S. endocrinologists.^[1] It is also the second most common branded therapy prescribed by primary care physicians when adding or switching therapies in patients.^[2] Since its launch, more than one million prescriptions have been written for INVOKANA^®.^[3]

The co-administration of INVOKANA^® and metformin has been studied in six Phase 3 clinical studies that enrolled 4,732 patients with type 2 diabetes. The Phase 3 studies evaluated INVOKANA^® in combination with metformin compared to metformin alone or to metformin plus another diabetes therapy. The studies were part of the comprehensive global Phase 3 program for INVOKANA^®that enrolled 10,285 patients, one of the largest clinical programs in type 2 diabetes submitted to health authorities to date. The Phase 3 studies showed that the combination of INVOKANA^® and metformin lowered blood sugar and, in pre-specified secondary endpoints, was associated with significant reductions in body weight and systolic blood pressure.

In two studies comparing INVOKANA^® plus metformin to current standard treatments plus metformin – one studying sitagliptin and the other studying glimepiride – INVOKANA^® dosed at 300 mg provided greater reductions in A1C levels and body weight than either comparator. A1C is the percent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose over the previous two to three months. In the two studies, the overall incidence of adverse events was similar with INVOKANA^® and the comparators.

Results from the Phase 3 studies showed that the most common adverse events with INVOKANA^® are female genital mycotic (fungal) infections, urinary tract infections and increased urination. These specific adverse events were generally mild to moderate in intensity and infrequently led to discontinuation in Phase 3 studies. The most common adverse reactions due to initiation of metformin, as noted in the prescribing information for that medication, are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use. INVOKANA^® can increase the risk of hypoglycemia when combined with insulin or a medication that increases insulin levels (e.g., a sulfonylurea). Therefore, a lower dose of insulin or insulin-raising medication may be required to minimize the risk of hypoglycemia when used in combination with INVOKAMET^™.

Janssen Pharmaceuticals, Inc. and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.

On April 25, 2014, Janssen-Cilag International NV announced that the European Commission (EC) approved VOKANAMET^® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycemic control. INVOKANA^® is approved as a single agent in Aruba, Australia, Brazil, Canada, Chile, Costa Rica, El Salvador, the European Union (31 countries), Guatemala, Kuwait, Mexico, Peru, Singapore, South Korea, Switzerland, United Arab Emirates, and the United States.

About Type 2 Diabetes

An estimated 371 million people worldwide are living with diabetes^{^[4]} and approximately 29 million people have diabetes in the United States.^[5] Type 2 diabetes comprises 90 to 95 percent of people with diabetes,^[5] which is chronic and affects the body’s ability to metabolize sugar (glucose), and is characterized by the inability of pancreatic beta cell function to keep up with the body’s demand for insulin.

Nearly half of adults with type 2 diabetes do not achieve recommended levels of glucose control, and if left uncontrolled, type 2 diabetes can lead to serious complications.^{^[6]}^{,^[7],^[8]} Improved glycemic control has been demonstrated to reduce the onset and progression of these complications.^{^[9]}

WHAT IS INVOKAMET^™?

INVOKAMET^™contains two prescription medicines called canagliflozin (INVOKANA^®) and metformin hydrochloride (GLUCOPHAGE^®). It is used along with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes when treatment with either canagliflozin or metformin, or both medications, has not controlled your blood sugar. INVOKAMET^™ is not for people with type 1 diabetes or with diabetic ketoacidosis (increased ketones in blood or urine). It is not known if INVOKAMET^™ is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

INVOKAMET^™ can cause serious side effects, including:

Lactic Acidosis. Metformin, one of the medicines in INVOKAMET^™, can cause a rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital. Stop taking INVOKAMET^™ and call your doctor right away if you have any of the following symptoms which could be signs of lactic acidosis: feel very weak or tired; have unusual (not normal) muscle pain; have trouble breathing; have unusual sleepiness or sleep longer than usual; have stomach pains, nausea, or vomiting; feel dizzy or lightheaded; or have a slow/irregular heartbeat

You have a higher chance of getting lactic acidosis with INVOKAMET^™ if you have conditions such as: kidney problems, or your kidneys are affected by certain X-ray tests that use injectable dye; liver problems; congestive heart failure; drink alcohol very often, (or drink a lot of alcohol in short-term); get dehydrated; have surgery; have a heart attack, severe infection, or stroke; or are 80 years of age or older and have not had your kidneys tested.

Do not take INVOKAMET^™ if you:

Have severe kidney problems or are on dialysis, have a condition called metabolic acidosis or diabetic ketoacidosis (increased ketones in the blood or urine). Are allergic to canagliflozin, metformin, or any of the ingredients in INVOKAMET^™. See the end of the Medication Guide for a list of ingredients in INVOKAMET^™. Symptoms of allergic reaction may include: rash; raised red patches on your skin (hives); swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing

Before you take INVOKAMET^™, tell your doctor if you: have kidney problems, have liver problems, are on a low sodium (salt) diet, have ever had an allergic reaction to INVOKAMET^™, or are going to get an injection of dye or contrast agents for an X-ray procedure (INVOKAMET^™ will need to be stopped for a short time); have heart problems (including congestive heart failure); drink alcohol very often (or drink a lot of alcohol in short term); or have any other medical conditions.

Tell your doctor if you are or plan to become pregnant, are breastfeeding or plan to breastfeed. It is not known if INVOKAMET^™ will harm your unborn baby. It is also not known if INVOKAMET^™ passes into your breast milk.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take: diuretics (water pills), rifampin (used to treat or prevent tuberculosis), phenytoin or phenobarbital (used to control seizures), ritonavir (Norvir^®, Kaletra^®, Lopinavir^®-used to treat HIV infection), or digoxin (Lanoxin^®– used to treat heart problems).

Possible Side Effects of INVOKAMET^™

INVOKAMET^™ may cause serious side effects, including: dehydration– INVOKAMET^™ can cause some people to have dehydration (the loss of body water and salt), kidney problems, a high amount of potassium in your blood (hyperkalemia), liver problems, or low blood sugar (hypoglycemia). If you take INVOKAMET^™ with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKAMET^™.

Signs and symptoms of low blood sugar may include: headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, shaking or feeling jittery.

Vaginal yeast infection: Women taking INVOKAMET^™ may get vaginal yeast infections. Symptoms include: vaginal odor, white or yellowish discharge, or vaginal itching.

Yeast infection of the penis (balanitis or balanoposthitis): Men taking INVOKAMET^™ may get a yeast infection of the skin around the penis. Symptoms include: redness, itching, or swelling of the penis; rash; foul smelling discharge; or pain in the skin around penis.

Serious allergic reaction: If you have any symptoms of a serious allergic reaction, stop taking INVOKAMET^™ and call your doctor right away or go to the nearest hospital emergency room.

Low vitamin B₁₂ (vitamin B₁₂ deficiency): Using metformin for long periods of time may cause a decrease in the amount of vitamin B₁₂ in your blood. Your doctor may do blood tests to check your levels.

The most common side effects of INVOKAMET^™include: urinary tract infection; changes in urination, including urgent need to urinate more often, in larger amounts, or at night; diarrhea, nausea and vomiting, gas, weakness, indigestion, upset stomach, or headache.

Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736.

Please see the full Product Information, including Boxed Warning, and Medication Guide.

WHAT IS INVOKANA^®?

INVOKANA^® is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA^® is not for people with type 1 diabetes or with diabetic ketoacidosis (increased ketones in blood or urine). It is not known if INVOKANA^® is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

INVOKANA^® can cause important side effects, including:

Dehydration (the loss of body water and salt), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). You may be at higher risk of dehydration if you have low blood pressure, take medicines to lower your blood pressure (including diuretics [water pills]), are on a low sodium (salt) diet, have kidney problems, or are 65 years of age or older
Vaginal yeast infection. Women who take INVOKANA^® may get vaginal yeast infections. Symptoms include: vaginal odor, white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese), or vaginal itching
Yeast infection of the penis (balanitis or balanoposthitis). Men who take INVOKANA^® may get a yeast infection of the skin around the penis. Symptoms include: redness, itching, or swelling of the penis; rash of the penis; foul-smelling discharge from the penis; or pain in the skin around penis

Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis.

Do not take INVOKANA^® if you:

are allergic to canagliflozin or any of the ingredients in INVOKANA^®. Symptoms of allergic reaction may include: rash; raised red patches on your skin (hives); or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing
have severe kidney problems or are on dialysis

Before you take INVOKANA^®, tell your doctor if you have kidney problems, liver problems, are on a low sodium (salt) diet, ever had an allergic reaction to INVOKANA^®, or have other medical conditions.

Tell your doctor if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed. It is not known if INVOKANA^® will harm your unborn baby. It is also not known if INVOKANA^® passes into your breast milk.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take diuretics (water pills), rifampin (used to treat or prevent tuberculosis), phenytoin or phenobarbital (used to control seizures), ritonavir (Norvir^®, Kaletra^®, Lopinavir^® – used to treat HIV infection), or digoxin (Lanoxin^® – used to treat heart problems).

Possible Side Effects of INVOKANA^®

INVOKANA^® may cause serious side effects, including: kidney problems, a high amount of potassium in your blood (hyperkalemia), or low blood sugar (hypoglycemia). If you take INVOKANA^® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKANA^®.

Signs and symptoms of low blood sugar may include: headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, shaking, or feeling jittery.

Serious allergic reaction. If you have any symptoms of a serious allergic reaction, stop taking INVOKANA^® and call your doctor right away or go to the nearest hospital emergency room.

The most common side effects of INVOKANA^® include: vaginal yeast infections and yeast infections of the penis; urinary tract infection; or changes in urination, including urgent need to urinate more often, in larger amounts, or at night.

Please see the full Prescribing Information and Medication Guide.

Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.

Trademarks are those of their respective owners.

About Janssen Pharmaceuticals, Inc.

As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Pharmaceuticals, Inc. is dedicated to addressing and resolving the major unmet medical needs of our time. Driven by our commitment to patients, healthcare professionals, and caregivers, we strive to develop sustainable and integrated healthcare solutions by working in partnership with all stakeholders on the basis of trust and transparency. Our daily work is guided by meeting goals of excellence in quality, innovation, safety, and efficacy in order to advance patient care.

For more information on Janssen Pharmaceuticals, Inc., visit us at www.janssenpharmaceuticalsinc.com or follow us on Twitter at www.twitter.com/JanssenUS and on YouTube at www.Youtube.com/JanssenUS.

*Dr. Aguilar was not associated with the INVOKANA^® clinical trials and was not compensated for any media work. He has been a paid consultant to Janssen Pharmaceuticals, Inc.

[1] Data on file. Based on NBRx data sourced from IMS NPA Market Dynamics Database, weekly data, showing INVOKANA^® has been the leading branded non-insulin type 2 diabetes medication newly prescribed by U.S. endocrinologists for eight weeks, through July 25, 2014, the most recent data available at time of approval of INVOKAMET™.

[2] Data on file. Based on NBRx data sourced from IMS NPA Market Dynamics Database, weekly data through July 25, 2014

[3] Data on file. Based on total prescription data sourced from IMS NPA National Database, weekly data through July 25, 2014.

[4] International Diabetes Federation, Diabetes Atlas 5th Edition 2012 Update, New estimates for 2012 of diabetes prevalence, mortality, and healthcare expenditures. Available at: http://www.idf.org/sites/default/files/5E_IDFAtlasPoster_2012_EN.pdf.

[5] Centers for Disease Control and Prevention, National Diabetes Statistics Report, 2014. Available at: http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf

[6] Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63-71.

[7] Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013 Feb 15. Epub ahead of print.

[8] World Health Organization, Media Centre, Diabetes, Fact sheet Number 312. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed April 1, 2013.

[9] Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.

Acura Launches All-New 2015 TLX Performance Luxury Sedan With Biggest Marketing Campaign in Brand History

August 11, 2014

Acura 2015 TLX Luxury Sedan — Acura Launches All-New 2015 TLX Performance Luxury Sedan With Biggest Marketing Campaign in Brand History

Acura Launches All-New 2015 TLX Performance Luxury Sedan With Biggest Marketing Campaign in Brand History

— Acura TLX delivers “It’s that kind of thrill” in 360-degree campaign

— “My Way” anthem spot captures passion of U.S. team of engineers and designers who developed the TLX

— Bite-sized and clever creative deployed across multiple platforms for sustained launch effort through fall

TORRANCE, Calif., Aug. 11, 2014 /PRNewswire-HISPANIC PR WIRE/ — Acura is launching the all-new 2015 TLX performance luxury sedan with the biggest marketing campaign in the brand’s history. The TLX, which combines sports-sedan dynamic proportion, premium luxury refinement and super-handling performance, is the star of a 360-degree marketing campaign under the theme “It’s that kind of thrill.”

Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-LA87356-20140811-1.mp4

Photo – http://photos.prnewswire.com/prnh/20140811/134943

Logo – http://photos.prnewswire.com/prnh/20100923/ACURALOGO

The marketing campaign launches on-air August 17 with the TV anthem spot, “My Way,” which captures the passion of the team of Acura design, development and manufacturing engineers who created the new TLX. The emotionally engaging spot features a modern rendition of the iconic song My Way as the soundtrack for images shot onsite at the R&D and manufacturing facilities that were integral to the TLX development. “My Way,” and eight additional 15-second spots featuring high-energy music tracks, will run on high-profile national TV programming throughout the late summer and fall.

“The TLX heralds a new era for the Acura sedan lineup and the scale of the marketing effort behind the launch signifies the importance of the model both to the brand and its position within the luxury sedan market,” said Michael Accavitti, senior vice president and general manager for the Acura division.

“The TLX delivers a thrill like no other and the marketing effort delivers that message front and center in an emotionally engaging way.”

The entire campaign utilizes ‘bite-sized’ contextually relevant video and digital elements that demonstrate the thrill of driving the new TLX by focusing on specific product highlights, including on-board Siri Eyes Free voice-command capability, Precision All-Wheel Steer™ (P-AWS™) and the Acura exclusive, Super Handling All-Wheel Drive (SH-AWD™).

Integrated Media Placements and Digital Extensions

Acura will run a massive video road block on Facebook with TLX videos reaching nearly 100% of users starting in early September. On Twitter, Acura will run a unique Twitter Cards execution that will allow users to design a car directly within a Tweet. Acura will be using both Promoted Tweets and Promoted Accounts to support this initiative.

Additional awareness for the TLX will be generated via homepage takeovers on major web portals (Yahoo and MSN), and through unique social media “Thrillustrations” – custom illustrations created by New Yorker contributing illustrators. TLX will also be supported with custom digital content on Slate, Business Insider and Car & Driver.

The TLX will be front and center on cable television with “My Way” running concurrently across more than 25 cable networks starting on August 17th. Additionally, the TLX will be integrated into ESPN’s SportsCenter with a month long sponsorship of top college football highlights.

To get customers up close to the TLX, the model will be the featured vehicle at The New Yorker Festival in October and the Sundance Institute NextFest film festival in Los Angeles in August. Acura is also sponsoring a series of Pop-Up dinners across the country and select nights at the Hollywood Bowl; each venue prominently features the TLX. To capture attention on a large scale, TLX will be featured on several large wallscapes, billboards and street level displays in nine key markets.

To see featured video elements from the TLX “It’s that kind of thrill” campaign visit https://www.youtube.com/user/Acura and all campaign creative elements at http://acuracampaigns.com/.

About the 2015 TLX
The all-new 2015 TLX was designed to deliver a unique and compelling blend of sports-sedan dynamic proportion, premium luxury refinement and super-handling performance, appealing to a broad cross-section of luxury customers with three all-new powertrains and advanced chassis technologies that respond intelligently to the will of the driver. The TLX lineup features three distinct model offerings that deliver new levels of quietness and ride comfort for a luxurious driving experience.

About Acura
Acura offers a full line of technologically advanced performance-luxury vehicles through a network of approximately 270 U.S. Acura dealers. The Acura lineup features five distinctive models – the RLX luxury flagship sedan, the TLX performance luxury sedan, the ILX compact luxury sedan, the 5-passenger RDX luxury crossover SUV, and the 7-passenger Acura MDX, America’s all-time best-selling three-row luxury SUV. Acura was recently recognized by Edmunds.com for the third consecutive year as leading all luxury brands in retained value after five years of ownership. More than 90 percent of the Acura vehicles sold in America are produced at the company’s manufacturing facilities in America, using domestic and globally sourced parts.

For More Information
Consumer information about Acura is available at acura.com. To join the Acura community on Facebook, visit facebook.com/Acura. Additional media information including detailed features, pricing and high-resolution photography of the Acura model line is available at acuranews.com.

NOTE TO EDITORS: High-resolution images are available at: http://hispanicprwire.com/en/multimedia/

Watch Spanish Singer Antonio Orozco’s ‘Terra Live Music in Studio’ Performance, Presented By Sprint

August 11, 2014

ANTONIO OROZCO1 — Antonio Orozco to Perform on 'Terra Live Music in Studio'

Watch Spanish Singer Antonio Orozco’s ‘Terra Live Music in Studio’ Performance, Presented By Sprint

Pop Sensation to Perform Hit Singles “Llegara,” “Devuelveme la Vida,” “Ya lo Sabes” and “No Hay Mas”

MIAMI, Aug. 11, 2014 /PRNewswire-HISPANIC PR WIRE/ — Terra announces the Spanish pop star, ANTONIO OROZCO, as the next artist to perform on the “Terra Live Music in Studio” stage, presented by Sprint. The latest installment from “Terra Live Music” will feature hit singles from Orozco’s platinum album “Dos Orillas.” The concert airs via live stream on Thursday, August 21 at 8pm EST. Fans around the world can enjoy the performance at www.Terra.com.

The Spanish pop star, known for his contagiously energetic and passionate performances will take his talents to the “Terra Live Music” stage during an intimate show where he will perform his #1 international hits “Devuelveme la Vida,” “Llegara,” “Ya lo Sabes,” “No Hay Mas” and “Estoy Hecho de Pedacitos de Ti.”

Inspired by his exposure to flamenco rhythms, Antonio Orozco shares the traditional sounds of his Catalonia origins on the Terra stage. This acoustic performance places Antonio Orozco among the repertoire of superstars that have participated in “Terra Live Music in Studio”, “Terra Live Music in Concert” and “Terra Live Music Home Sessions” with Terra, the leading global media company for Hispanics in the U.S. and Latin America.

Antonio Orozco has established an international presence over the past ten years, with over 600,000 albums sold, including both Platinum and Gold records. The artist received a Premio Ondas award for “Best Artist,” a “Premio Tu Musica” award for his single “Devuelveme la Vida” and was nominated for a Latin Grammy in 2012 for the “Best Song of the Year” category. In addition to his debut album “Dos Orillas” reaching #1 in Spanish album sales becoming a platinum album within two weeks, the release maintained its #1 status in iTunes Spain for over a week.

Don’t miss the amazing “Terra Live Music in Studio” with Antonio Orozco on Thursday, August 21 at 8:00pm EST. Get social with @TerraMusicaUS and @Antoniorozco about #TerraLiveMusic as you watch the show LIVE on any of your devices.

The unforgettable night can be enjoyed by fans around the world exclusively on www.Terra.com.

About Terra

Created in 1999, Terra is the leading digital content producer in Spanish and Portuguese speaking countries, reaching a monthly audience of over 100 million people. Terra reaches users through editorial content and is a pioneer in sports and entertainment live transmissions – from live concerts performed by artists like Paul McCartney, U2, Alejandro Sanz, Juanes and Kings of Leon, to European League and championship matches as well as the Olympic Games. Terra’s content is offered in English, Spanish and/or Portuguese in 19 countries across the United States, Latin America and Europe, through multiple screens – computers, tablets and smartphones. Led by the Global CEO, Paulo Castro, Terra’s headquarters are in Sao Paulo, Brazil, and the company has offices in Argentina, Chile, Colombia, Mexico, Peru, Spain and the United States.

Terra has launched a new responsive layout providing an innovative content and advertising delivery with the objective to simplify user’s lives and allowing advertisers to reach consumers in a whole new way.

“Terra. Your World, Simplified.” Visit the New Terra at www.Terra.com or click here for more information on “Terra Live Music”.

About Universal Music Group

Universal Music Group is the world’s leading music company with wholly owned operations in 60 territories. Its businesses also include Universal Music Publishing Group, the industry’s leading global music publishing operation.

Universal Music Group’s record labels include A&M/Octone, Decca, Def Jam Recordings, Deutsche Grammophon, Disa, Emarcy, Fonovisa, Geffen Records, Interscope Records, Island Records, Lost Highway Records, Machete Music, MCA Nashville, Mercury Nashville, Mercury Records, Motown Records, Polydor Records, Universal Music Latino, Universal Republic and Verve Music Group as well as a multitude of record labels owned or distributed by its record company subsidiaries around the world. The Universal Music Group owns the most extensive catalogue of music in the industry, which includes the last 100 years of the world’s most popular artists and their recordings. UMG’s catalogue is marketed through two distinct divisions, Universal Music Enterprises (in the U.S.) and Universal Strategic Marketing (outside the U.S.). Universal Music Group also includes Global Digital Business, its new media and technologies division and Bravado, its merchandising company.

Universal Music Group is a unit of Vivendi, a global media and communications company.

NOTE TO EDITORS: A high-resolution image is available at: http://hispanicprwire.com/en/multimedia/

SiriusXM and Global Music Superstar Pitbull to Create Exclusive SiriusXM Channel

August 11, 2014

Sirius Photo — SiriusXM and Global Music Superstar Pitbull to Create Exclusive SiriusXM Channel

SiriusXM and Global Music Superstar Pitbull to Create Exclusive SiriusXM Channel

Curated by Pitbull, the channel will be highlighted by a weekly show hosted by the international pop star

NEW YORK, Aug. 11, 2014 /PRNewswire-HISPANIC PR WIRE/ — SiriusXM announced today it has joined with global music superstar Pitbull to create a channel featuring music by the international pop star as well as his personal musical selections.

Photo – http://photos.prnewswire.com/prnh/20140811/135032

Photo – http://photos.prnewswire.com/prnh/20101014/NY82093LOGO

The channel will be curated and presented by the pop star and entrepreneur and will feature music from across multiple genres exclusively for SiriusXM listeners. The channel will be anchored by a weekly show hosted by Pitbull. The new channel will be infused with Pitbull’s music – from his early days in Miami through his meteoric rise to international fame and his current hits. In addition, the artist will share music by fellow musicians.

Pitbull’s channel is scheduled to debut in early 2015.

“We are thrilled to team up with Pitbull in the creation of this exciting new music channel that will reach his massive audience. Pitbull is truly ‘Mr. Worldwide,’ and his music and collaborations have drawn legions of fans who will now have access to a full-time channel that he is creating especially for them,” said Scott Greenstein, President and Chief Content Officer, SiriusXM. “Pitbull will bring the excitement and energy of his live appearances to the channel, only on SiriusXM.”

“First of all, I want to thank SiriusXM for the opportunity to touch my fans in a more personal way,” said Pitbull (Armando Christian Perez). “I will also get a chance to play all the music that I love and grew up listening – most of all, we are going to have a lot of fun in the process – so, preparense [get ready] y daleeeeee.”

Armando Christian Perez aka Pitbull is a musician, performer, entrepreneur, and actor with career sales in excess of 5 million albums and over 60 million singles worldwide. Pitbull has had #1 hits in more than 15 countries, his videos have over 5 billion views and his social reach exceeds 78 million followers. His latest album, Global Warming: Meltdown features the hit singles “Feel This Moment” with Christina Aguilera, “Don’t Stop The Party,” “Back In Time” and his second #1 hit on the Billboard Hot 100 chart “Timber” featuring Ke$ha. Pitbull’s world tours have sold out concerts in North and South America, Europe, and the Far East. Recently, Pitbull performed the official anthem “We Are One (Ole Ola)” with Jennifer Lopez and Claudia Leitte at the opening ceremony of the FIFA World Cup in Brazil. A burgeoning entrepreneur, Pitbull has his own line of premium vodkas (Voli); partnerships with Playboy Enterprises and Sheets, the dissolvable energy strip; and, premier fragrances for men and women. He recently confirmed a fall co-headline U.S./Canada arena tour with Enrique Iglesias.

Pitbull’s channel is an example of SiriusXM channels created with iconic and prominent artists, including Bruce Springsteen’s E Street Radio, Jimmy Buffett’s Radio Margaritaville, Willie Nelson’s Roadhouse, The Pink Floyd Channel, B.B, King’s Bluesville, Elvis Radio, Siriusly Sinatra, Ozzy Osbourne’s Ozzy’s Boneyard, Pearl Jam Radio, Eminem’s Shade 45, Tiesto’s Club Life Radio and Neil Diamond Radio.

For more information, please visit www.pitbullmusic.com and www.siriusxm.com.

About SiriusXM

Sirius XM Holdings Inc. (NASDAQ: SIRI) is the world’s largest radio broadcaster measured by revenue and has more than 26.3 million subscribers. SiriusXM creates and broadcasts commercial-free music; premier sports talk and live events; comedy; news; exclusive talk and entertainment; and the most comprehensive Latin music, sports and talk programming in radio. SiriusXM is available in vehicles from every major car company in the U.S. and from retailers nationwide as well as at shop.siriusxm.com. SiriusXM programming is available through the SiriusXM Internet Radio App for smartphones and other connected devices as well as online at siriusxm.com. SiriusXM also provides premium traffic, weather, data and information services for subscribers in cars, trucks, RVs, boats and aircraft through SiriusXM Traffic™, SiriusXM Travel Link, NavTraffic®, NavWeather™, SiriusXM Aviation, SiriusXM Marine™, Sirius Marine Weather, XMWX Aviation™, and XMWX Marine™. SiriusXM holds a minority interest in SiriusXM Canada which has more than 2 million subscribers.

On social media, join the SiriusXM community on Facebook, Twitter, Instagram, and YouTube.

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results may differ materially from the results anticipated in these forward-looking statements.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: our competitive position versus other radio and audio entertainment providers; our ability to attract and retain subscribers, which is uncertain; our dependence upon the auto industry; general economic conditions; failure of our satellites, which, in most cases, are not insured; the interruption or failure of our information and communications systems; the security of the personal information about our customers; royalties we pay for music rights, which increase over time; the unfavorable outcome of pending or future litigation; our failure to realize benefits of acquisitions; rapid technological and industry change; failure of third parties to perform; changes in consumer protection laws and their enforcement; failure to comply with FCC requirements and other government regulations; and our indebtedness. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2013, which is filed with the Securities and Exchange Commission (the “SEC”) and available at the SEC’s Internet site (http://www.sec.gov). The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this communication.

P-SIRI

Contacts:
Michelle Dominguez
212.901.6792
[email protected]

Tom Muzquiz
323-337-6563
[email protected]

NOTE TO EDITORS: High-resolution images are available at: http://hispanicprwire.com/en/multimedia/

Statement by Dr. Samuel Rodriguez, President of the National Hispanic Christian Leadership Conference on Passing of Robert Gittelson

August 11, 2014

National Hispanic Christian Leadership Conference logo.

Statement by Dr. Samuel Rodriguez, President of the National Hispanic Christian Leadership Conference on Passing of Robert Gittelson

SACRAMENTO, California, Aug. 11, 2014 /PRNewswire-HISPANIC PR WIRE/ — Dr. Samuel Rodriguez made the following statement today following the death of his close friend and colleague Robert Gittelson. Gittelson served on the board of directors of NHCLC/Conela and was vice president for government affairs.

“Robert Gittelson was more than the vice president for governmental affairs. He was my friend, brother and co-laborer. His commitment and advocacy on behalf of religious liberty, immigrants, righteousness and justice made him a prominent voice on Capitol Hill. I loved him and will miss him beyond imagination. This I can say about Robert without any hesitation; he loved God, his family and the least of these. Robert did justice, loved mercifully, and walked humbly before God. Our prayers and love are with Patty and the rest of the family during this difficult time,” said Dr. Samuel Rodriguez, president of NHCLC/Conela.

Mr. Gittelson was a leader within the fight for immigration reform. He aggressively met with senators, congressmen, the White House administration and their staffs, participating in well over 300 meetings in the nation’s capital, strongly advocating for a legislative solution to the immigration crisis in America and on behalf of the unaccompanied children at the border.

“Robert Gittelson was an outstanding leader and follower of Jesus with a heart to serve others, especially the Latino evangelical community. We will greatly miss him,” said Dr. Albert L. Reyes, president and CEO of Buckner International and member of the NHCLC/Conela board of directors.

“Robert Gittelson was a tireless professional who relentlessly pursued immigration justice for those who had been manacled by the system he strove to change for the better. When immigration reform comes to the United States, politicians, students, and all who fought for change will remember Robert Gittelson and know his clarion call for reform was finally heard,” said Dr. Carlos Campo.

An alumnus of the University of Southern California, Robert Gittelson spent almost 30 years as an apparel manufacturer and importer. He built his business working shoulder to shoulder with immigrants and had a thorough understanding of the value that the immigrant population brings to the economy, as well as society. A frequent speaker at symposiums and panel discussions across America on immigration across America, he was the author of more than 80 published articles, essays, and journal articles on the subject of comprehensive immigration reform. As President of Conservatives for Comprehensive Immigration Reform, Gittelson was also a founding member of the Evangelical Immigration Table.

Upon joining NHCLC, Robert Gittelson said, “In meeting Samuel Rodriguez in early 2010, I realized that he was blessed by God to be a natural leader. As we worked together on immigration, we slowly developed an appreciation for the goals that we shared, not just on immigration, but on larger societal goals as well.

“When Samuel asked that I join him as the vice president for governmental affairs for the NHCLC, he asked that I pray on my decision, and I did,” Gittelson continued. “I am certain that the Lord intends for me to continue to work with the NHCLC, and I am committed to work tirelessly in support of the goals and aspirations of that worthy and noble institution.”

Robert Gittelson resided with Patricia, his wife of 31 years, in Los Angeles, California. Patricia is a practicing immigration attorney. Together with Gittelson they have two adult sons, Alex, a graduate of the University of Southern California, and Jesse, a graduate of Carnegie Mellon University.

NHCLC/Conela is the largest Hispanic Christian organization serving millions of Evangelicals, 40,118 U.S. churches and more than 500,000 churches across the globe. Seeking to reconcile evangelist Billy Graham’s message of salvation with Dr. Martin Luther King, Jr.’s march of prophetic activism, the NHCLC/Conela emphasizes “7 Directives” of Life, Family, Compassionate Evangelism, Stewardship, Justice, Education and Youth. For additional information, visit http://www.nhclc.org.

(Español) Inspirate este verano con la nueva fragancia de Avon Flor Alegria

August 11, 2014

Sorry, this entry is only available in Español.

1...3,1083,1093,110...3,139 Page 3,109 of 3,139